$0.34
-0.01 (-3.55%)
HCWB News2 articles
HCW Biologics Surges 262% on Trimmune Deal and Profit, Nasdaq Risk Looms
HCW Biologics shares jumped 262% after a licensing deal with Beijing Trimmune Biotech fueled a Q1 profit. The company still faces Nasdaq delisting risks and will seek shareholder approval for a reverse stock split.
HCW Biologics Posts Profit on China Deal, Faces Nasdaq and Pipeline Tests
HCW Biologics posted a $3.47M profit in Q1 2026, driven by a licensing deal with Trimmune Biotech. The company still trades below Nasdaq's $1 minimum and awaits early human data for its lead alopecia drug.